Correction: Enzymatic assays for the diagnosis of bradykinin-dependent angioedema (PLoS ONE (2013) 8, 8, (e70140) DOI: 10.1371/journal.pone.0070140);Enzymatic Assays for the Diagnosis of Bradykinin-Dependent Angioedema

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Defendi, Federica ^a,b   Charignon, Delphine ^a,b   Ghannam, Arije ^b   Baroso, Remi ^b   Csopaki, Françoise ^a   Allegret Cadet, Marion ^a   Ponard, Denise ^a   Favier, Bertrand ^b   Cichon, Sven ^c,d   Nicolie, Brigitte ^a,e   Fain, Olivier ^a,f   Martin, Ludovic ^a,e   Drouet, Christian ^a,b  

^a French Reference Centre of Kinin Mediated Angio Oedemas   (France)

^b UNIV GRENOBLE ALPES   (France)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; ANTIBODY; BRADYKININ; CONTRACEPTIVE AGENT; ENZYME PRECURSOR; ESTROGEN; HIGH MOLECULAR WEIGHT KININOGEN ANTIBODY; KALLIKREIN; PROLYLPHENYLALANYLARGININE 4 NITROANILIDE; TETRAPEPTIDE; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IMMUNOBLOTTING; LIMIT OF DETECTION; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AMIDOHYDROLASES; COMPLEMENT C1 INACTIVATOR PROTEINS; FEMALE; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; IMMUNOBLOTTING; KININS; MALE; PREGNANCY;

EID: 84881095783     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100345     Document Type: Erratum

References (31)

1. Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis LJ Jr, et al. (1983) Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 308: 1050-1053 doi:10.1056/NEJM198305053081802.
2. Björkqvist J, Sala-Cunill A, Renné T (2013) Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 109. doi:10.1160/TH12-08-0549.
3. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, et al. (2005) The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 99: 6-38.
4. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, et al. (2007) Nonallergic angioedema: role of bradykinin. Allergy 62: 842-856 doi:10.1111/j.1398-9995.2007.01427.x.
5. Renné T, Gruber A, (2012) Plasma kallikrein: novel functions for an old protease. Thromb Haemost 107: 1012-1013 doi:10.1160/TH12-04-0264.
6. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M, (2009) C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 15: 69-78 doi:10.1016/j.molmed.2008.12.001.
7. Castelli R, Deliliers DL, Zingale LC, Pogliani EM, Cicardi M, (2007) Lymphoproliferative disease and acquired C1 inhibitor deficiency. Haematologica 92: 716-718.
8. Jackson J, Sim RB, Whelan A, Feighery C, (1986) An IgG autoantibody which inactivates C1-inhibitor. Nature 323: 722-724 doi:10.1038/323722a0.
9. Caballero T, Baeza ML, Cabañas R, Campos A, Cimbollek S, et al. (2011) Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol 21: 333-347; quiz follow 347.
10. Martin L, Degenne D, Toutain A, Ponard D, Watier H, (2001) Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission. J Allergy Clin Immunol 107: 747-748.
11. Bork K, Barnstedt S-E, Koch P, Traupe H, (2000) Hereditary angioedema with normal C1-inhibitor activity in women. The Lancet 356: 213-217 doi:10.1016/S0140-6736(00)02483-1.
12. Binkley KE, Davis III A, (2000) Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. Journal of Allergy and Clinical Immunology 106: 546-550 doi:10.1067/mai.2000.108106.
13. Cichon S, Martin L, Hennies HC, Müller F, Van Driessche K, et al. (2006) Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79: 1098-1104 doi:10.1086/509899.
14. Bork K, Wulff K, Hardt J, Witzke G, Staubach P, (2009) Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 124: 129-134 doi:10.1016/j.jaci.2009.03.038.
15. Martin L, Raison-Peyron N, Nöthen MM, Cichon S, Drouet C, (2007) Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. J Allergy Clin Immunol 120: 975-977 doi:10.1016/j.jaci.2007.07.002.
16. Zuraw BL, Bork K, E Binkley K, Banerji A, Christiansen SC, et al. (2012) Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. Allergy Asthma Proc. doi:10.2500/aap2012.33.3627.
17. Vitrat-Hincky V, Gompel A, Dumestre-Perard C, Boccon-Gibod I, Drouet C, et al. (2010) Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy 65: 1331-1336 doi:10.1111/j.1398-9995.2010.02368.x.
18. Kluft C, (1978) Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein. J Lab Clin Med 91: 83-95.
19. Armbruster DA, Pry T, (2008) Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29Suppl 1: S49-52.
20. Giard C, Nicolie B, Drouet M, Lefebvre-Lacoeuille C, Le Sellin J, et al. (2012) Angio-oedema induced by oestrogen contraceptives is mediated by bradykinin and is frequently associated with urticaria. Dermatology (Basel) 225: 62-69 doi:10.1159/000340029.
21. Bork K, Fischer B, Dewald G, (2003) Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 114: 294-298.
22. Frank MM, Gelfand JA, Atkinson JP, (1976) Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 84: 580-593.
23. Joseph K, Tuscano TB, Kaplan AP, (2008) Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Annals of Allergy, Asthma & Immunology 101: 279-286 doi:10.1016/S1081-1206(10)60493-0.
24. Berrettini M, Lämmle B, White T, Heeb MJ, Schwarz HP, et al. (1986) Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 68: 455-462.
25. Cugno M, Cicardi M, Coppola R, Agostoni A, (1996) Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 33: 361-364.
26. Imamura T, Dubin A, Moore W, Tanaka R, Travis J, (1996) Induction of vascular permeability enhancement by human tryptase: dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab Invest 74: 861-870.
27. Oschatz C, Maas C, Lecher B, Jansen T, Björkqvist J, et al. (2011) Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34: 258-268 doi:10.1016/j.immuni.2011.02.008.
28. Dlamini Z, Bhoola KD, (2005) Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. J Clin Pathol 58: 915-922 doi:10.1136/jcp.2004.021444.
29. Ishizaka T, Iwata M, Ishizaka K, (1985) Release of histamine and arachidonate from mouse mast cells induced by glycosylation-enhancing factor and bradykinin. J Immunol 134: 1880-1887.
30. McGlinchey PG, McCluskey DR, (2000) Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman. Am J Med Sci 320: 212-213.
31. Citarella F, Misiti S, Felici A, Farsetti A, Pontecorvi A, et al. (1996) Estrogen induction and contact phase activation of human factor XII. Steroids 61: 270-276.